NPPA and depressive symptom measurement: Under cytokine stimulation, IDO is upregulated in patients with depression, which abnormally activates the KP metabolic pathway, interferes with the transmission of serotonin and glutamate neurotransmitters, and induces neurological manifestations, leading to pain hypersensitivity and depressive symptoms (75).